Viatris Inc. Raises 2026 Outlook Amid Mixed Q2 Performance
Viatris Inc. (Nasdaq: VTRS) increased its 2026 revenue guidance to $3.8 billion after reporting a second‑quarter net loss of $118.8 million, a significant decline from the $4.6 million loss recorded a year earlier. The company highlighted a $177.8 million non‑cash charge related to the planned sale of a business segment, which contributed to the larger loss.
Q2 2026 Financial Highlights
| Metric | Q2 2026 | Q2 2025 (Year‑over‑Year) |
|---|---|---|
| Total revenue | $3.8 billion | $3.6 billion (+5 %) |
| Adjusted EBITDA | $1.2 billion | $1.1 billion (+8 %) |
| GAAP net loss | $119 million | $4.6 million |
| Diluted loss per share | $0.10 | < $0.01 |
The company also noted that sales of its new fast‑acting meloxicam reached $500 million in peak projections, reinforcing the outlook for the remainder of the year. This product launch was part of a broader strategy to strengthen the generics portfolio, although analysts observed a softening in generic margins that could temper long‑term growth.
Divestitures and Strategic Focus
Viatris announced a divestiture that is expected to streamline its operations and improve profitability. The sale is part of a wider initiative to sharpen focus on core therapeutic areas, including non‑communicable and infectious diseases. The divestiture proceeds are anticipated to reduce the company’s operating expenses and support the enhanced guidance.
Pipeline and Regulatory Milestones
The company reported key milestones in its pipeline, including the U.S. FDA approval of an eye drug, Tyrvaya, which has been sold to Harrow for up to $100 million. Additionally, Viatris achieved record sales for its second‑quarter pipeline, with new product launches contributing to the revenue increase. The company’s pipeline continues to include developments in the areas of dermatology and ophthalmology.
Market Context
Despite the upward revision of its guidance, the market reaction to the earnings report was muted. Nasdaq shares fell approximately 0.4 % in early trade, reflecting investor concerns about the ongoing headwinds in the second half of the year. Analysts noted that the company’s guidance remains optimistic, yet the non‑cash charge and divestiture impacts could lead to a more conservative outlook in the coming quarters.
Conclusion
Viatris Inc. has positioned itself for stronger 2026 performance by raising its revenue guidance, executing a strategic divestiture, and advancing its pipeline. While the second‑quarter results included a significant net loss due to a non‑cash charge, the company’s adjusted EBITDA and new product sales support a positive long‑term trajectory. Investors will likely monitor the impact of the divestiture and the execution of the new product launches as key drivers of future profitability.
